Anzeige
Mehr »
Login
Sonntag, 28.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Fokus auf Nurexone: High-Level Biotech im Pennystock-Kleid!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
17 Leser
Artikel bewerten:
(0)

ResMed Announces Conference Call And Webcast To Discuss Second Quarter 2014 Results

SAN DIEGO, Dec. 18, 2013 /PRNewswire/ -- RESMED INC. (NYSE: RMD) announced today that on Thursday, January 23, 2014, it will release its results for the second quarter and six months of fiscal year 2014, ended December 31, 2013. A press release with ResMed's results will be issued after 1:00 p.m. US Pacific Time and the company will host a conference call and webcast to review its results, market trends, and future outlook.

(Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

The conference call is scheduled to begin at 1:30 p.m. US Pacific Time and will be webcast on ResMed's website at http://investor.resmed.com. Please go to this section of the website 5-10 minutes before the call and click on the icon for the "Q2 2014 results webcast." The online archive of the broadcast will be available approximately 30 minutes after the live call and will continue to be available for two weeks.

International conference call times will be:

9:30 p.m.

London

8:30 a.m.

Sydney, Australia (January 24, 2014)

TO PARTICIPATE in the conference call, please call one of the numbers below at least 10 minutes before the call begins and identify yourself to the operator:

US:

847-585-4405

Outside US:

+1 847-585-4405

Conference Name:

Q2 2014 ResMed Inc. Results Conference Call

Participant Passcode:

36303553

The replay of the conference call will be available approximately 30 minutes after the call and will be accessible for two weeks at:

US:

630- 652-3042

Outside US:

+1 630-652-3042

Passcode:

36303553

ResMed is a global leader in the development, manufacturing, and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing.

Further information can be obtained by contacting Constance Bienfait at ResMed Inc. at +1 (858) 836-5971, or by visiting the company's website at www.resmed.com.

SOURCE ResMed Inc.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2013 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.